Related Experiment Video
Updated: Jun 2, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Gender effect on time to levodopa-induced dyskinesias
Sharon Hassin-Baer1, Irena Molchadski, Oren S Cohen
1Department of Neurology, Parkinson and Movement Disorders Clinic, Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel-Hashomer, 52621 Ramat-Gan, Israel. shassin@post.tau.ac.il
Journal of Neurology
|May 3, 2011
Summary
Female Parkinson's patients develop levodopa-induced dyskinesias (LID) sooner. Younger age at Parkinson's disease diagnosis and delayed levodopa treatment also increase LID risk.
Area of Science:
- Neurology
- Pharmacology
Background:
- Levodopa-induced dyskinesias (LID) are a common complication in Parkinson's disease (PD) management.
- Factors influencing the time to LID onset remain unclear, particularly non-pharmacological influences.
Purpose of the Study:
- To identify factors associated with the time to the appearance of levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) patients.
- To explore the relationship between potential risk factors and LID onset latency.
Main Methods:
- Historical prospective analysis of 155 consecutive PD patients treated with levodopa.
- Comparison between LID and non-LID groups.
- Kaplan-Meier method and Cox multivariate regression analysis to explore risk factors, controlling for gender, age of onset, time to levodopa initiation, and smoking history.
Main Results:
- 57.4% of patients developed LID.
- Patients with LID were significantly younger at disease onset.
- Female gender was associated with a shorter time to LID (median 4 years vs. 6 years for males).
- Younger age at PD diagnosis and longer latency to levodopa treatment were linked to shorter time to LID appearance.
Conclusions:
- Female gender is a significant risk factor for a shorter latency to LID.
- Earlier age at Parkinson's disease diagnosis and delayed initiation of levodopa treatment are associated with both a higher likelihood of developing LID and a shorter time to its appearance.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.